Sherry Weigand, Ph.D.
Sherry Weigand is the Vice President of Clinical Science at Seres. She is a pharmaceutical industry executive with 20+ years of experience and accomplishments – Seres Therapeutics, Shire, Baxalta, Takeda, Novo Nordisk and Procter and Gamble Pharmaceutical. Prior to Seres, Sherry was a Global Program Lead and Global Clinical Development Lead at Shire, Baxalta, and Takeda, overseeing clinical development programs across multiple therapeutic areas, including neurological disorders, immunological and inflammatory diseases, metabolic disease, vaccine, gene therapy for hemophilia disease and microbiome therapy. In these roles, she successfully led global teams through all phases of clinical development, global regulatory submissions and label negotiation for product registrations in the U.S., EU, Japan, and China. Sherry also previously served as a medical doctor at Beijing Chao-Yang Hospital in China. Sherry received a Bachelor of Medicine from Beijing Medical College and a Ph.D. in Microbiology and Immunology from Louisiana State University. She completed a postdoctoral fellowship at the University of Pittsburg Medical School, focusing on humoral immune response to HIV infection.